ArticleJAC-antimicrobial resistance2026
Molecular epidemiology and resistance mechanisms of carbapenem-resistant Gram-negative bacilli in a referral hospital in Lima, Peru.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Gram-negative bacilli (CR-GNB) represent a significant public health threat, as they are associated with high mortality in healthcare settings. Carbapenemase production is the predominant resistance mechanism, and horizontal gene transfer drives the rapid dissemination of antimicrobial resistance (AMR). Objectives: This study aimed to characterize the phenotypic and genotypic AMR profiles of CR-GNB isolated from patients at Arzobispo Loayza National Hospital (Lima, Peru) between October 2021 and January 2022. Methods: We conducted a cross-sectional study and collected clinical and epidemiological data from patients with bacterial infections. MALDI-TOF identified pathogens, and antimicrobial susceptibility was interpreted according to CLSI guidelines. A subset of isolates underwent whole-genome sequencing (Illumina) to determine genomic resistance markers. Results: A total of 159 patients were included (median age = 54 years; 66.7% male); 72.3% had confirmed clinical infections, and 66% were admitted to the ICU. The most frequent infection types were pneumonia, urinary tract infection and bacteraemia. Overall, 97.5% of isolates were classified as XDR. Carbapenem resistance approached 100% (imipenem 99.4%, meropenem 98.7%). Whole-genome data revealed clonal diversity among Conclusions: These findings demonstrate a critical burden of XDR-GNB and the presence of multiple carbapenemases (NDM, IMP, KPC and VIM) associated with clinically relevant high-risk lineages. Strengthening molecular surveillance, optimizing antimicrobial stewardship and reinforcing infection-control measures are urgently needed to contain CR-GNB in critical-care settings in Peru.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.